Yanyu Zhang1,2, Yuan Xie1, Liqun He3,4, Jiefu Tang5, Qiyuan He1, Qingze Cao1, Langjun Cui1, Wei Guo6, Kai Hua7, Anna Dimberg4, Liang Wang8, Lei Zhang9,10. 1. Key Laboratory of Ministry of Education for Medicinal Plant Resource and Natural Pharmaceutical Chemistry, National Engineering Laboratory for Resource Developing of Endangered Chinese Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an, 710119, China. 2. Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Biomedical Center, Box 582, BMC, Husargatan 3, 75123, Uppsala, Sweden. 3. Department of Neurosurgery, Tianjin Medical University General Hospital, Tianjin Neurological Institute, Key Laboratory of Post-Neuro-injury Neuro-Repair and Regeneration in Central Nervous System, Ministry of Education and Tianjin City, Tianjin, 300052, China. 4. Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Rudbeck Laboratory, 75185, Uppsala, Sweden. 5. Department of Spine Surgery, Huaihua No.2 Hospital, Hunan University of Medicine, Huaihua, 418000, China. 6. Department of Neurosurgery, Tangdu Hospital, Air Force Medical University of PLA (the Fourth Military Medical University), 569 Xinsi Road, Xi'an, 710038, China. 7. The College of Life Sciences, Northwest University, Xi'an, 710069, China. 8. Department of Neurosurgery, Tangdu Hospital, Air Force Medical University of PLA (the Fourth Military Medical University), 569 Xinsi Road, Xi'an, 710038, China. drwangliang@126.com. 9. Key Laboratory of Ministry of Education for Medicinal Plant Resource and Natural Pharmaceutical Chemistry, National Engineering Laboratory for Resource Developing of Endangered Chinese Crude Drugs in Northwest of China, College of Life Sciences, Shaanxi Normal University, Xi'an, 710119, China. lei.zhang@snnu.edu.cn. 10. Department of Spine Surgery, Huaihua No.2 Hospital, Hunan University of Medicine, Huaihua, 418000, China. lei.zhang@snnu.edu.cn.
Abstract
BACKGROUND: Tumor-associated macrophages (TAM)s are critical regulators of glioma progression. As yet, however, TAMs in isocitrate dehydrogenase (IDH) mutated lower-grade gliomas (LGGs) have not been thoroughly investigated. The aim of this study was to determine whether 1p/19q co-deletion status affects the TAM phenotype or its prevalence in IDH mutated LGGs. METHODS: TAMs in IDH mutated LGGs were analyzed using transcriptome data from 230 samples in the TCGA database in combination with transcriptome data from single-cell RNA sequencing of IDH-mutated LGGs. Proteins potentially involved in TAM regulation were examined by immuno-staining in primary LGG samples harboring IDH mutations. Essential signaling pathways regulating TAM phenotypes were investigated in a glioma mouse model using small molecule inhibitors. RESULTS: Most of the TAMs in IDH-mutated LGGs expressed the M1 activation markers CD86 and TNF, whereas a subset of individual TAMs co-expressed both M1 and M2-related markers. Bioinformatics analysis in combination with immuno-staining of IDH-mutated patient samples revealed higher amounts of TAMs expressing M2-related markers in 1p/19q non-codeletion IDH-mutated LGGs compared to 1p/19q codeletion LGGs. The levels of transforming growth factor beta 1 (TGFβ1) and macrophage colony-stimulating factor (M-CSF) were significantly higher in 1p/19q non-codeletion LGGs than in 1p/19q codeletion LGGs. M-CSF and TGFβ1 signal inhibition decreased tumor growth and modulated the TAM phenotype in a glioma mouse model. CONCLUSIONS: Our data indicate that 1p/19q co-deletion status relates to distinct TAM infiltration in gliomas, which is likely mediated by M-CSF and TGFβ1 signaling. M-CSF and TGFβ1 signaling may play a pivotal role in regulating the TAM phenotype in glioma.
BACKGROUND:Tumor-associated macrophages (TAM)s are critical regulators of glioma progression. As yet, however, TAMs in isocitrate dehydrogenase (IDH) mutated lower-grade gliomas (LGGs) have not been thoroughly investigated. The aim of this study was to determine whether 1p/19q co-deletion status affects the TAM phenotype or its prevalence in IDH mutated LGGs. METHODS:TAMs in IDH mutated LGGs were analyzed using transcriptome data from 230 samples in the TCGA database in combination with transcriptome data from single-cell RNA sequencing of IDH-mutated LGGs. Proteins potentially involved in TAM regulation were examined by immuno-staining in primary LGG samples harboring IDH mutations. Essential signaling pathways regulating TAM phenotypes were investigated in a gliomamouse model using small molecule inhibitors. RESULTS: Most of the TAMs in IDH-mutated LGGs expressed the M1 activation markers CD86 and TNF, whereas a subset of individual TAMs co-expressed both M1 and M2-related markers. Bioinformatics analysis in combination with immuno-staining of IDH-mutated patient samples revealed higher amounts of TAMs expressing M2-related markers in 1p/19q non-codeletion IDH-mutated LGGs compared to 1p/19q codeletion LGGs. The levels of transforming growth factor beta 1 (TGFβ1) and macrophage colony-stimulating factor (M-CSF) were significantly higher in 1p/19q non-codeletion LGGs than in 1p/19q codeletion LGGs. M-CSF and TGFβ1 signal inhibition decreased tumor growth and modulated the TAM phenotype in a gliomamouse model. CONCLUSIONS: Our data indicate that 1p/19q co-deletion status relates to distinct TAM infiltration in gliomas, which is likely mediated by M-CSF and TGFβ1 signaling. M-CSF and TGFβ1 signaling may play a pivotal role in regulating the TAM phenotype in glioma.
Authors: David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison Journal: Acta Neuropathol Date: 2016-05-09 Impact factor: 17.088
Authors: Salvatore J Coniglio; Eliseo Eugenin; Kostantin Dobrenis; E Richard Stanley; Brian L West; Marc H Symons; Jeffrey E Segall Journal: Mol Med Date: 2012-05-09 Impact factor: 6.354
Authors: Susobhan Sarkar; Axinia Döring; Franz J Zemp; Claudia Silva; Xueqing Lun; Xiuling Wang; John Kelly; Walter Hader; Mark Hamilton; Philippe Mercier; Jeff F Dunn; Dave Kinniburgh; Nico van Rooijen; Stephen Robbins; Peter Forsyth; Gregory Cairncross; Samuel Weiss; V Wee Yong Journal: Nat Neurosci Date: 2013-12-08 Impact factor: 24.884
Authors: Elizabeth B Claus; Kyle M Walsh; John K Wiencke; Annette M Molinaro; Joseph L Wiemels; Joellen M Schildkraut; Melissa L Bondy; Mitchel Berger; Robert Jenkins; Margaret Wrensch Journal: Neurosurg Focus Date: 2015-01 Impact factor: 4.047
Authors: D S Markovic; K Vinnakota; S Chirasani; M Synowitz; H Raguet; K Stock; M Sliwa; S Lehmann; R Kälin; N van Rooijen; K Holmbeck; F L Heppner; J Kiwit; V Matyash; S Lehnardt; B Kaminska; R Glass; H Kettenmann Journal: Proc Natl Acad Sci U S A Date: 2009-07-15 Impact factor: 11.205
Authors: Benjamin C Kennedy; Christopher R Showers; David E Anderson; Lisa Anderson; Peter Canoll; Jeffrey N Bruce; Richard C E Anderson Journal: J Oncol Date: 2013-05-08 Impact factor: 4.375